Xencor | XNCR - Cost Of Sales



Xencor reported 61.66M in Cost of Sales for its fiscal quarter ending in June of 2025.


Cost Of Sales Change Date
AbbVie USD 4.35B 344M Jun/2025
Alnylam Pharmaceuticals USD 142.95M 71.91M Jun/2025
Amgen USD 3.01B 406M Jun/2025
AstraZeneca USD 2.47B 232M Jun/2025
Biogen USD 605M 24.3M Jun/2025
Bristol-Myers Squibb USD 3.37B 339M Jun/2025
Cytokinetics 112.55M 12.71M Jun/2025
GlaxoSmithKline GBP 2.16B 241M Jun/2025
J&J USD 7.6B 304M Jun/2025
MacroGenics USD 49.7M 44.21M Jun/2025
Merck USD 2.82B 53M Jun/2025
Novartis USD 3.32B 95M Jun/2025
Pfizer USD 4.99B 2.4B Jun/2025
Regeneron Pharmaceuticals USD 530.2M 264.7M Jun/2025
Roche Holding CHF 4.13B 393.5M Dec/2024
Xencor 61.66M 50.95M Jun/2025